Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03825289 · ClinicalTrials.gov registry record · Phase 1
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
A Phase 1 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, sponsored by University of Utah.
- Active
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT03825289 is a Phase 1 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 25 participants, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03825289, a Phase 1 study of Stage IV Pancreatic Cancer and Stage III Pancreatic Cancer, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib together with hydroxychloroquine may work better in treating patients with pancreatic cancer.
Conditions Studied
Interventions
- DRUG Trametinib
- DRUG Hydroxychloroquine
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-01-18 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03825289
The ClinicalTrials.gov registry entry for NCT03825289 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (68% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Trametinib is the first listed.
NCT03825289 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Utah.
Frequently Asked Questions
What is clinical trial NCT03825289 about?
NCT03825289 is a clinical study titled "Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer". This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery. Trametinib may stop the growth ...
What is the current status of trial NCT03825289?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-01-18. Estimated completion is 2029-03.
What conditions does trial NCT03825289 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Unresectable Pancreatic Carcinoma, Stage II Pancreatic Cancer.
What interventions are being tested in trial NCT03825289?
The interventions under investigation include: Trametinib (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT03825289?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03825289 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
COMPLETED · Phase 1
-
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
COMPLETED · Phase 1
-
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.